Form D · Biotechnology
Elicio Therapeutics, Inc.
Boston, MA · CIK 0001555192
Offering snapshot reported Nov 2, 2022 · SEC filing
- Reported sold
- $22M Offering amount: $50M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 12, 2022 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$974,999 → $21,995,420
- Reported investors3 → 7
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 2, 2022 | Amendment | $21,995,420 | $21,020,421vs May 27, 2022 | 7 | SEC filing |
| May 27, 2022 | Initial | $974,999 | No comparison | 3 | SEC filing |
| Nov 18, 2021 | Amendment | $14,470,000 | $0vs Nov 12, 2021 | 4 | SEC filing |
| Nov 12, 2021 | Amendment | $14,470,000 | $12,470,000vs Oct 19, 2021 | 4 | SEC filing |
| Oct 19, 2021 | Initial | $2,000,000 | No comparison | 1 | SEC filing |
| Jul 15, 2020 | Initial | $6,085,000 | No comparison | 49 | SEC filing |
| Mar 13, 2020 | Initial | $8,411,801 | No comparison | 108 | SEC filing |
| Oct 15, 2019 | Initial | $7,000,000 | No comparison | 2 | SEC filing |
| Sep 14, 2018 | Initial | $25,817,848 | No comparison | 137 | SEC filing |
| Aug 3, 2018 | Initial | $14,492,501 | No comparison | 115 | SEC filing |
| Jun 5, 2018 | Initial | $2,990,000 | No comparison | 27 | SEC filing |
| May 24, 2016 | Initial | $750,000 | No comparison | 1 | SEC filing |
| Jul 31, 2012 | Initial | $3,300,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $990K (estimated)
- Form D file number
- 021-447361
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Finalis Securities LLC | 305908 |
Source: Form D, filed Nov 2, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Julian Adams | Director |
| Carol Ashe | Director |
| Daniel Behr | Director |
| Isaac Blech | Director |
| Ben Bronstein | Director |
| Yekaterina Chudnovsky | Director |
| Robert Connelly | Director, Executive |
| Steve Deitcher | Director |
| Daniel Geffken | Director, Executive |
| Ofer Gonen | Director |
| Frank Haluska | Director |
| Christopher Haqq | Executive |
| Satish Jindal | Director |
| Daphne Karydas | Director |
| Isaac Kohlberg | Director |
| William Koster | Director |
| Annette Matthies | Executive |
| Robert Ruffolo | Director |
| Assaf Segal | Director |
| Alan Shaw | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
451 D Street 5 Th Floor, Suite 501
Boston, MA, 02210
Boston, MA, 02210